Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~- Participants with primary hypercholesterolemia treated with atorvastatin at stable dose of 5-20 mg for at least 6 weeks prior to screening and likely to have LDL-C ≥100 mg/dL (≥2.59 mmol/L) at the screening visit.~OR~- Participants with primary hypercholesterolemia who were receiving a lipid-lowering treatment other than atorvastatin, or who were not at stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening if they were likely to have LDL-C ≥100 mg/dL (≥2.59 mmol/L) after a 6-week run-in treatment period on atorvastatin therapy.~Exclusion criteria:~1. LDL-C \<100 mg/dL (\<2.59 mmol/L)~   * at screening visit for participants who were being treated with stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening OR~  * at the end of the 6-week run-in period on atorvastatin for participants receiving a lipid lowering treatment other than atorvastatin, or not at stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening~2. Participants with type 1 diabetes~3. Participants with type 2 diabetes treated with insulin, or without, and considered poorly controlled at screening.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 50 mg Q2W (Type: EXPERIMENTAL): Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 75 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 150 mg Q2W (Type: PLACEBO_COMPARATOR): Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).